EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial

Hanrong Cheng, Liying Deng, Zili Meng, Wei Zhang, Tao Chen, Rui Chen, Shiyou Tang, Yunhui Lv, Xiaoli Su, Zhifen Liu, Xiaoqing Zhang, Xueyi Wang und 15 weitere

CNS Drugs · 2026

DOI: 10.1007/s40263-025-01232-1 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift CNS Drugs, 2026. Verfasst von Hanrong Cheng und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Sleep Medicine, Institute of Respiratory Diseases, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University,…. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Disorders of Excessive Somnolence, Carbamates. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ignis Therapeutics (Suzhou) Limited, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Excessive daytime sleepiness (EDS) is a prominent symptom of obstructive sleep apnea (OSA), negatively affecting patients' quality of life. The objective of this study was to assess the efficacy and safety of solriamfetol in patients with OSA with EDS from China. METHODS: This multicenter, randomized, double-blind, placebo-controlled phase 3 trial compared solriamfetol (75/150 mg once daily) with placebo for 12 weeks. Adults diagnosed with OSA, mean Maintenance of Wakefulness Test (MWT) sleep latency < 30 min, and Epworth Sleepiness Scale (ESS) score ≥ 10 were included. Patients with disorders causing EDS other than OSA were excluded. Co-primary endpoints were change from baseline to week 12 in MWT mean sleep latency and ESS score; a key secondary endpoint was improvement on Patient Global Impression of Change (PGI-C), assessed on a seven-point scale. MWT was performed at baseline and at weeks 2, 5, and 12, whereas the ESS and PGI-C were evaluated at weeks 2, 5, 8, and 12. Safety and tolerability were assessed on the basis of treatment-emergent adverse events (TEAEs), laboratory tests, vital signs, 24-h ambulatory blood pressure monitoring, 12-lead electrocardiogram, and physical examination. Statistical analyses of co-primary endpoints were performed on the full analysis set (FAS) using a mixed model for repeated measures (MMRM). Safety analyses were performed on the safety population. A hierarchical testing sequence was used to control multiplicity. RESULTS: Of the 204 patients randomized (1:1) into placebo and solriamfetol groups, 192 completed the study (96 in each group). Co-primary endpoints were met, with significantly increased mean MWT sleep latency (P < 0.0001) and decreased ESS score (P = 0.0017) in the solriamfetol group (MWT, n = 95; ESS, n = 97) versus placebo (MWT, n = 95; ESS, n = 96) at week 12. Higher proportion of participants receiving solriamfetol (n = 90; 89.1%) reported improvement in PGI-C versus placebo (n = 77; 77.0%; P = 0.0221). At least one TEAE was reported in solriamfetol (n = 84; 82.4%) and placebo (n = 67; 65.7%) groups. The occurrence of serious TEAEs was low, with one incidence in both groups. Most frequently reported TEAEs in solriamfetol group included upper respiratory tract infection, dizziness, hyperuricemia, hypertension, hyperlipidemia, hypertriglyceridemia, and increased blood creatine phosphokinase. Most TEAEs were of mild/moderate severity and did not lead to study treatment discontinuation. CONCLUSIONS: Solriamfetol demonstrated substantial efficacy and acceptable safety in Chinese patients with OSA with EDS, reinforcing its role as a viable treatment option. TRIAL REGISTRATION: ClinicalTrials.gov: NCT06103825.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Apnea, ObstructiveDisorders of Excessive SomnolenceCarbamatesHumansDouble-Blind MethodMaleFemaleMiddle AgedChinaAdultTreatment OutcomeAgedQuality of LifePhenylalanine

Substanzen

solriamfetolCarbamatesPhenylalanine

Autor:innen und Institutionen

  • Department of Sleep Medicine, Institute of Respiratory Diseases, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and T…
  • Department of Neurology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Department of Respiratory and Critical Care Medicine, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huaian, Jiangsu, China.
  • Department of Neurology, Yan'an University Xianyang Hospital, Xianyang, China.
  • The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Sleep Center, The Second Affiliated Hospital of Soochow University, Suzhou, China.

ORCID-Profile: Weifeng Mi

Förderung

  • Ignis Therapeutics (Suzhou) Limited, China

Zitieren

APA

Cheng, H., Deng, L., Meng, Z., Zhang, W., Chen, T., Chen, R., Tang, S., Lv, Y., Su, X., Liu, Z., Zhang, X., Wang, X., Mao, H., Zhang, N., Yu, H., Pan, J., Xie, Y., Tang, J., Yin, S., …, & Lu, L. (2026). Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial. CNS Drugs. https://doi.org/10.1007/s40263-025-01232-1

Vancouver

Cheng H, Deng L, Meng Z, Zhang W, Chen T, Chen R, et al. Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial. CNS Drugs. 2026. doi:10.1007/s40263-025-01232-1

BibTeX
@article{Cheng2026,
  author = {Cheng, Hanrong and Deng, Liying and Meng, Zili and Zhang, Wei and Chen, Tao and Chen, Rui and Tang, Shiyou and Lv, Yunhui and Su, Xiaoli and Liu, Zhifen and Zhang, Xiaoqing and Wang, Xueyi and Mao, Hongjing and Zhang, Nuofu and Yu, Huan and Pan, Jiyang and Xie, Yuping and Tang, Jiyou and Yin, Shankai and Wang, Zan and Tong, Maoqing and Zhan, Shuqin and Wang, Chunxue and Wang, Bei and Zhang, Weihua and Mi, Weifeng and Lu, Lin},
  title = {Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial},
  journal = {CNS Drugs},
  year = {2026},
  doi = {10.1007/s40263-025-01232-1}
}
Kostenlos starten →